Loading...
Market
Story
Neuralink's Coin-Sized N1 Implant with 1,024 Electrodes Enables Thought-Controlled Computing at 9.5 BPS
Dec 14, 2024, 11:25 PM
Neuralink's N1 implant is being hailed as a groundbreaking advancement in brain-computer interface technology. The device, which is the size of a coin, features 1,024 ultra-thin electrodes that can read neural signals, allowing individuals with paralysis to control computers, play games, and type through thought alone. With a bandwidth of 9.5 bits per second, the N1 device achieves approximately 50% of normal human capability. The technology is positioned as a significant step forward in merging human cognition with machines, with potential applications in technology, medicine, and human evolution. Neuralink's recent developments have garnered attention, particularly in light of its FDA milestones and the ongoing discussions surrounding its impact on enhancing human potential.
View original story
Similar markets
Assistive technology for paralysis • 25%
Cognitive enhancement • 25%
Medical treatment for neurological disorders • 25%
Other • 25%
Medical (e.g., helping paralyzed individuals) • 25%
Gaming • 25%
Communication • 25%
Other • 25%
Gaming and digital device control • 25%
Medical applications • 25%
Research and development • 25%
Other • 25%
Gaming • 25%
Virtual Reality • 25%
Augmented Reality • 25%
Other • 25%
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Medical rehabilitation • 25%
Gaming and entertainment • 25%
Industrial and design applications • 25%
Other • 25%
Restoration of hand movement • 25%
Restoration of leg movement • 25%
Improvement in speech • 25%
Other • 25%
Very Positive • 25%
Somewhat Positive • 25%
Neutral • 25%
Negative • 25%
Communication enhancement for ALS patients • 25%
Cognitive enhancement for general users • 25%
Control of tech devices like Apple Vision Pro • 25%
Medical research and trials • 25%
Restoring eyesight to a blind individual • 25%
Enhancing vision for partially sighted individuals • 25%
Other medical applications • 25%
No application by end of 2024 • 25%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trial halted • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trial not completed • 25%